Searchable abstracts of presentations at key conferences in endocrinology

ea0090p92 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

A study to evaluate clinical and metabolic profile in a type 1 diabetes cohort receiving dpp4 inhibitor plus SGLT2 inhibitor compared to either drug alone as an adjuvant therapy

Dev K Chethan , Kumar Sethi Bipin

Introduction: There is always been a need for safe and effective adjuvant therapy in type 1 Diabetes not just for glycemic control but also for cardio-renal benefits.Objectives: To evaluate whether addition of DPP-4 inhibitors reduces the ketogenic potential of SGLT2i when used as an adjuvant therapy in type 1 Diabetes.Materials & Methods: 20 type 1 Diabetes subjects above 18 years of age with poorly controlled glycemia (HbA1c ...